Morale is low at the FDA, which was hit with layoffs this week following RFK Jr.’s confirmation. Biopharma leaders and agency insiders fear further workforce cuts could delay new medicines.
FDA Reels From ‘Indiscriminate’ Job Cuts Under Trump as Biopharma Appeals for Clarity Read More »
BridgeBio beat investor expectations with 1,028 unique prescriptions for ATTR-CM therapy Attruby, setting the company up to beat a 2025 sales consensus of $86 million.
BridgeBio Stock Hits 1-Year High as Attruby Rx Numbers Double Read More »
The meeting, which will include Pfizer CEO Albert Bourla as the newly named board of directors’ chair, will reportedly cover key topics for the lobbying group, including the Inflation Reduction Act.
Newly Stacked PhRMA to Meet With Trump on IRA, Other Policies Read More »
FTC Chair Andrew Ferguson sent a memo to agency staff on Tuesday clarifying that the Biden-era guidelines will remain in place — for now.
FTC retains stricter merger guidelines under Trump Read More »
Despite expectations of dealmaking leniency, new FTC chairman Andrew Ferguson told staff that he will retain the current 2023 FTC and DOJ guidelines on mergers, upholding stricter anti-trust scrutiny on deals.
FTC Doubles Down on Tighter Merger Rules Despite Trump’s Pro-Industry Posture Read More »
Despite the regulatory setback, analysts appear optimistic, noting that Harmony’s long-term prospects remain bright given the development of its high-dose formulation of its sleep-regulating drug Wakix.
FDA Kicks Down Harmony’s Bid to Push Wakix Into Idiopathic Hypersomnia Read More »
A year ago, AstraZeneca walked away from the bulk of its roxadustat partnership with FibroGen—though the pharma at the time decided to retain its relationship with the biotech’s China operations.
AstraZeneca Buys FibroGen’s China Unit for $160M as Probes Continue Read More »
Looking for a biopharma job in Pennsylvania? Check out the BioSpace list of six companies hiring life sciences professionals like you.
After SPN-820’s failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s therapy Onapgo to sustain the company.
Supernus Falls Back on CNS Portfolio as Depression Drug Fails Mid-Stage Study Read More »
The Philadelphia market has gained recognition not only for its cell and gene therapy sector but also its real estate scene and talent pool. Vittoria Biotherapeutics, Interius BioTherapeutics and Chamber of Commerce for Greater Philadelphia executives share why the area is a life sciences hot spot.
Philadelphia’s Life Sciences Scene Making Its Mark Read More »
